Recent studies have proven that the purinergic signaling pathway plays a key role in neurotransmission and neuromodulation, and is involved in various neurodegenerative diseases and psychiatric disorders. With the characterization of the subtypes of receptors in purinergic signaling, i.e. the P1 (adenosine), P2X (ion channel) and P2Y (G protein-coupled), more attention has been paid to the pathophysiology and therapeutic potential of purinergic signaling in the central nervous system disorders. Alzheimer’s disease (AD) is a progressive and deadly neurodegenerative disease that is characterized by memory loss, cognitive impairment and dementia. However, as drug development aimed to prevent or control AD has series of failures in recent years, more researchers have focused on the neuroprotection-related mechanisms such as purinergic signaling in AD patients to find a potential cure. This article reviews the recent discoveries of purinergic signaling in AD, and summarizes the potential agents as modulators for the receptors of purinergic signaling in AD-related research and treatments. Thus, our paper provides an insight into purinergic signaling in the development of anti- AD therapies.

最近的研究证明，嘌呤能信号通路在神经传递和神经调节中起关键作用，并参与各种神经退行性疾病和精神疾病。随着嘌呤信号中受体亚型的表征，即 P1（腺苷）、P2X（离子通道）和 P2Y（G 蛋白偶联），更多地关注中枢嘌呤信号的病理生理学和治疗潜力。神经系统疾病。阿尔茨海默病 (AD) 是一种进行性和致命的神经退行性疾病，其特征是记忆力减退、认知障碍和痴呆。然而，近年来，随着旨在预防或控制 AD 的药物开发出现一系列失败，更多的研究人员将注意力集中在 AD 患者的嘌呤能信号等神经保护相关机制上，以寻找潜在的治疗方法。本文回顾了 AD 中嘌呤能信号传导的最新发现，并总结了在 AD 相关研究和治疗中作为嘌呤能信号传导受体调节剂的潜在药物。因此，我们的论文提供了对抗 AD 疗法开发中嘌呤能信号传导的见解。